← back to search

Yonatan Oster

Hebrew University of Jerusalem · IL
Area of research
Infectious Diseases · Molecular Medicine
Research interest
Research interests include Medicine, Coronavirus disease 2019 (COVID-19), Internal medicine, 2019-20 coronavirus outbreak, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and Cohort.
h-index
citations
526
works
26
NIH funding
primary concept
email

Recent publications

Human immunodeficiency virus-associated gut microbiome impacts systemic immunodeficiency and susceptibility to opportunistic gut infection
Nature Microbiology 2026cited by 2position: middledoi
Cardiac Manifestations of <i>Mycoplasma pneumoniae</i> Infections: A Cohort Study 2007–2024
Clinical Infectious Diseases 2025cited by 3position: middledoi
An Omics-Guided Investigation of a Hospital Outbreak Caused by <i>bla</i>NDM-1-Producing <i>Pseudocitrobacter faecalis</i>
The Journal of Infectious Diseases 2025cited by 3position: middledoi
Colostrum from MERS-CoV seropositive camels for MERS prophylaxis and SARS-CoV-2 infection, a placebo controlled randomized trial
Scientific Reports 2025cited by 1position: middledoi
Randomized double-blind study on safety and tolerability of TP-102 phage cocktail in patients with infected and non-infected diabetic foot ulcers
Med 2024cited by 28position: middledoi
An international multicenter study comparing <scp>COVID</scp>‐19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab
Cancer Medicine 2024cited by 7position: middledoi
Diagnosis and Risk Factors of Prediabetes and Diabetes in People Living With Human Immunodeficiency Virus: Evaluation of Clinical and Microbiome Parameters
The Journal of Infectious Diseases 2024cited by 2position: middledoi
Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study
Infectious Diseases and Therapy 2024cited by 2position: middledoi
Refractory Pseudomonas aeruginosa infections treated with phage PASA16: A compassionate use case series
Med 2023cited by 52position: middledoi
Compassionate Use of Bacteriophages for Failed Persistent Infections During the First 5 Years of the Israeli Phage Therapy Center
Open Forum Infectious Diseases 2023cited by 50position: middledoi
Viral and Bacterial Respiratory Pathogens during the COVID-19 Pandemic in Israel
Microorganisms 2023cited by 11position: firstdoi
Sources of primary bloodstream infections in internal medicine patients – a cohort study
European Journal of Internal Medicine 2023cited by 9position: lastdoi
Real-Life Comparison of Fosfomycin to Nitrofurantoin for the Treatment of Uncomplicated Lower Urinary Tract Infection in Women
Biomedicines 2023cited by 2position: middledoi
Impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients: 3–5 months follow-up
Journal of Nephrology 2022cited by 21position: middledoi
The effect of a third BNT162b2 vaccine on breakthrough infections in health care workers: a cohort analysis
Clinical Microbiology and Infection 2022cited by 18position: firstdoi
A Case Report of Mycoplasma hominis Subdural Empyema Following Decompressive Craniotomy, and a Review of Central Nervous System Mycoplasma hominis Infections
Frontiers in Medicine 2022cited by 14position: lastdoi
Response to tozinameran (BNT162b2) booster in twice-vaccinated kidney transplant and maintenance dialysis patients
Journal of Nephrology 2022cited by 11position: middledoi
Native aortic valve <i>Staphylococcus warneri</i> endocarditis after COVID‐19 infection: a case report and a review of literature
Apmis 2022cited by 7position: middledoi
BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers
New England Journal of Medicine 2021cited by 143position: middledoi
Association Between Exposure Characteristics and the Risk for COVID-19 Infection Among Health Care Workers With and Without BNT162b2 Vaccination
JAMA Network Open 2021cited by 14position: firstdoi
Vancomycin-resistant enterococcus bacteraemia in an endemic region: clinical features and genomic analysis: a 12-year cohort
Journal of Hospital Infection 2021cited by 11position: middledoi
High attack rate of COVID-19 in an organized tour group of vaccinated travellers to Iceland
Journal of Travel Medicine 2021cited by 3position: lastdoi
Decreased prevalence rate of respiratory pathogens in hospitalized patients during the COVID-19 pandemic: possible role for public health containment measures?
Clinical Microbiology and Infection 2020cited by 52position: firstdoi
The molluscum contagiosum BOTE sign—Infected or inflamed?
Pediatric Dermatology 2020cited by 12position: middledoi
Keeping PPE barriers in COVID-19 wards while doing proper auscultation
Antimicrobial Resistance and Infection Control 2020cited by 4position: middledoi
A simplified blood culture sampling protocol for reducing contamination and costs: a randomized controlled trial
Clinical Microbiology and Infection 2019cited by 44position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Ran Nir‐Paz · Hebrew University of Jerusalem10 papers (2020–2025)Jacob Strahilevitz · Hebrew University of Jerusalem7 papers (2019–2025)Shmuel Benenson · Hebrew University of Jerusalem6 papers (2021–2023)Matan J. Cohen · Hebrew University of Jerusalem6 papers (2019–2023)Ayelet Michael-Gayego · Hebrew University of Jerusalem5 papers (2020–2025)Dana G. Wolf · Hebrew University of Jerusalem4 papers (2020–2023)Hila Elinav · Hebrew University of Jerusalem2 papers (2024–2025)Esther Oiknine‐Djian · Hebrew University of Jerusalem2 papers (2022–2022)Iddo Z. Ben‐Dov · Hebrew University of Jerusalem2 papers (2022–2022)Oshrat Ayalon · Hebrew University of Jerusalem2 papers (2022–2025)Hadas Pri-Chen · Hebrew University of Jerusalem2 papers (2022–2022)Michal Dranitzki Elhalel · Hebrew University of Jerusalem2 papers (2022–2022) · 2 papers (2021–2022)Keren Tzukert · Hebrew University of Jerusalem2 papers (2022–2022)Mila Rivkin · Hebrew University of Jerusalem2 papers (2020–2023)Assaf Potruch · Hebrew University of Jerusalem2 papers (2022–2022)Violeta Temper · Hebrew University of Jerusalem2 papers (2022–2025)Daniel Grupel · Hebrew University of Jerusalem2 papers (2025–2025)Michal Aharon · Hebrew University of Jerusalem2 papers (2022–2022)Alexander Rouvinski · Hebrew University of Jerusalem1 papers (2025–2025)